Cycle on Aug 24, 2026

I will begin the research cycle by listing the open threads and watches for this topic to see what specific questions or triggers need attention.

I will perform a web search to check for updates on the CARDIO-TTRansform trial results, which were scheduled to be presented at the ESC Congress 2026 in late August, and also run a general search for major science and health news from the past week.

I see that the ESC Congress 2026 runs from Friday, August 28 to Monday, August 31. The full dataset for the CARDIO-TTRansform trial is scheduled to be presented on August 28, 2026. Since today is August 24, 2026, the presentation has not yet occurred, but there is a lot of buzz about it. Let's do a search on other major science/health news from the past week to see what else might have broken. I will search for recent FDA decisions, clinical trials, or space/energy breakthroughs. Let's look for "FDA approval" or "Complete Response Letter" or "Phase 3 clinical trial".

This is a goldmine of recent news! Let's analyze the hits: 1. **Pasatru (garetosmab-grts)**: Approved by the FDA on August 19, 2026, for Fibrodysplasia Ossificans Progressiva (FOP). We have a watch for "Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP" (id `01a02ba3-c32b-7413-9840-06693a558ed9`). Garetosmab is approved! Let's fetch more information on this approval. 2. **Xspray Pharma receives Complete Response Letter (CRL) from FDA for Dasynoc**: Xspray Pharma received another CRL for Dasynoc! We have a watch for "Xspray Pharma NDA resubmission for Dasynoc" (id `01a030ca-9697-72f4-addf-96043b43eb73`). This watch was tracking the formal resubmission following the resolution of NerPharMa's manufacturing deficiencies, but they just got a CRL! Let's investigate this. 3. **Roche and Eli Lilly's Alzheimer's blood test (Elecsys pTau217)**: Approved by the FDA on August 24, 2026 (or very recently), marking another blood test for Alzheimer's. 4. **Ultragenyx Genglycos gene therapy (DTX401)**: Approved by the FDA on August 19, 2026, for Glycogen Storage Disease Type Ia (GSDIa) for patients aged 8 years and older. This is a major gene therapy approval! 5. **Johnson & Johnson's drug expanded approval for a rare blood disorder**: Let's find out what J&J drug got expanded approval. 6. **C2N Diagnostics' Alzheimer's test**: Approved on August 21, 2026. Let's do some specific fetches and searches on these. First, let's search for Xspray's CRL for Dasynoc. This is extremely relevant. Let's fetch the press release or related news. I will search for "Xspray" "Dasynoc" CRL 2026.

Excellent. We have a major CRL update for Xspray Pharma's Dasynoc, which was handed down on August 19, 2026. This is the fourth CRL/rejection (and second relating to NerPharMa manufacturing issues). Let's resolve the watch on Xspray Pharma's NDA resubmission (id `01a030ca-9697-72f4-addf-96043b43eb73`) or record an event. Wait, the watch was: "Monitor Xspray's formal resubmission of its NDA for Dasynoc to the FDA following the resolution of NerPharMa's manufacturing deficiencies and the generation of consecutive commercial-scale batch data." Wait, they already resubmitted earlier and just got a CRL on August 19, 2026! Let's record this event. The CRL was issued because of outstanding GMP observations at NerPharMa and a request for additional commercial-scale consecutive batch data. Xspray plans to resubmit again as soon as possible in 2026. Let's check the other news: - **Moderna and Merck say personalized melanoma cancer vaccine worked in late-stage trial**: Let's check this! We have a watch: "Merck and Moderna BLA submission for intismeran autogene mRNA cancer vaccine in melanoma" (id `01a01c33-a9b2-7ac7-b286-c7d9b8d78905`). Let's search for "Moderna" "Merck" melanoma trial results. This is a very big deal! Let's search.

This is a massive breakthrough! On August 19, 2026, Merck and Moderna announced that their Phase III INTerpath-001 trial of intismeran autogene (V940) plus Keytruda met its primary endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in patients with completely resected Stage IIB-IV melanoma. This is the first positive late-stage clinical trial result for a personalized mRNA cancer vaccine. Let's see if there are any details about the hazard ratio or other numbers, or if it was just a topline announcement. I will fetch the Merck press release or STAT News article to see what details they released. Let's fetch `https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/` using `web_fetch`. This is a primary source. Let's do it!

This is wonderful! We have a complete primary source for the Merck/Moderna INTerpath-001 trial readout. Let's look at the watch: "Merck and Moderna BLA submission for intismeran autogene mRNA cancer vaccine in melanoma" (id `01a01c33-a9b2-7ac7-b286-c7d9b8d78905`). It says: "Monitor the formal regulatory submission (BLA) of the Merck/Moderna mRNA cancer vaccine (intismeran autogene / V940) in combination with Keytruda for completely resected Stage IIB-IV melanoma to the FDA." Since they just announced positive Phase 3 results on August 19, 2026, and "plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions," we should keep this watch open but update/record an event or write a note about the Phase 3 clinical trial readout. This is a massive milestone! Let's write a note about this. Let's check the other news: - **Pasatru (garetosmab-grts)**: Approved by the FDA on August 19, 2026, for Fibrodysplasia Ossificans Progressiva (FOP). We have a watch: "Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP" (id `01a02ba3-c32b-7413-9840-06693a558ed9`). Garetosmab is approved! Let's search for "garetosmab" OR "Pasatru" FDA approval 2026. This is a major drug approval! Let's search.

This is fantastic! On August 19, 2026, the FDA approved Regeneron's **Pasatru (garetosmab-grts)** to reduce the formation of new abnormal bone growth (heterotopic ossification, HO) and clinician-assessed flare-ups in adults (18 years and older) with Fibrodysplasia Ossificans Progressiva (FOP). This is the second FDA-approved drug for FOP (following Ipsen's Sohonos/palovarotene in 2023), but it is the *first* to demonstrate a reduction in both new bone lesions and clinician-assessed flare-ups in a placebo-controlled Phase III trial (the OPTIMA trial). It is an intravenous activin A-neutralizing monoclonal antibody administered monthly. Let's check our watch: "Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP" (id `01a02ba3-c32b-7413-9840-06693a558ed9`). The watch was: "Monitor the initiation and enrollment of Regeneron's Phase III OPTIMA 2 clinical trial of Pasatru (garetosmab-grts) in pediatric and adolescent patients with fibrodysplasia ossificans progressiva (FOP)." Wait, since the current approval is only for adults (18+), let's search if there is any news on the OPTIMA-2 trial or pediatric trials. I'll search for "OPTIMA-2" OR "OPTIMA 2" "garetosmab" OR "Pasatru". Let's run a search.

Excellent! This confirms that garetosmab (Pasatru) was approved for adults on August 19, 2026, and the Phase III trial OPTIMA 2 for children/adolescents "is planned to begin later this year." So, since the OPTIMA 2 trial has not yet been initiated (it is planned to begin later this year), that watch `01a02ba3-c32b-7413-9840-06693a558ed9` should remain active. We can write a note about the adult FDA approval of Pasatru, which is a major regulatory milestone. Let's see if we have a prior finding for Pasatru or FOP. We don't have a prior finding, so we will mint a new slug: `regeneron-pasatru-garetosmab-fda-approval-fop`. Let's check the other news: - **Ultragenyx Genglycos gene therapy (DTX401)**: Approved by the FDA on August 19, 2026, for Glycogen Storage Disease Type Ia (GSDIa) for patients aged 8 years and older. Let's search for "Ultragenyx" "Genglycos" OR "DTX401" FDA approval 2026. This is another major gene therapy approval! Let's search.

This is another massive regulatory milestone! On August 19, 2026, the FDA granted accelerated approval to Ultragenyx's **Genglycos (pariglasgene brecaparvovec-opnr; DTX401)**, a one-time AAV8 gene therapy for adult and pediatric patients 8 years and older with glycogen storage disease type Ia (GSDIa). This is the first-ever FDA-approved treatment designed to treat the underlying cause of GSDIa (enzyme glucose-6-phosphatase deficiency). It reduces the daily cornstarch intake (which patients must consume round-the-clock to prevent life-threatening hypoglycemia). The approval list price is $2.7 million. The post-marketing study requirements to support conversion to traditional approval include providing two years of safety and efficacy clinical data from 50 patients who receive the therapy commercially and 20 control patients. Let's write a note about Genglycos, using the slug `ultragenyx-genglycos-gene-therapy-fda-approval-gsdia`. Let's check other news from the past week: - **J&J's drug expanded approval for a rare blood disorder**: Let's find out what J&J drug got expanded approval. I will search for "Johnson & Johnson" OR "J&J" FDA expanded approval 2026 rare blood disorder. Let's search.

Ah, let's search specifically for the Reuters article: "US FDA expands approval for J&J's drug for rare blood disorder" to see exactly what drug and what blood disorder. Let's do a search.

Let's fetch the Reuters article `https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-expands-approval-jjs-drug-rare-blood-disorder-2026-08-24/` to see the details of this expanded approval. This is extremely fresh (published today, August 24, 2026). Let's use `web_fetch`.

The Reuters article is extremely short and doesn't explicitly name the drug or the disorder in the text body (due to a brief wire report structure). Let's search the web for "Johnson & Johnson" "FDA" "expanded" "August 24, 2026" OR "August 2026" to find the press release or more complete articles. Let's do a search.

Wow! This is a massive hit! "FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients" The press release date is today, August 24, 2026. This is the first-ever treatment approved for warm autoimmune hemolytic anemia (wAIHA), a rare and serious blood disorder! And the drug is **IMAAVY (nipocalimab-aahu)**, an FcRn blocker developed by Johnson & Johnson. Let's fetch this press release `https://www.jnj.com/media-center/press-releases/fda-approves-imaavy-nipocalimab-aahu-as-first-ever-treatment-for-warm-autoimmune-hemolytic-anemia-waiha-representing-a-landmark-advancement-for-patients` using `web_fetch`. This is a primary source. Let's do it!

Ah, the URL returned 404, or the search budget is spent. Wait, the tool response says: "The web_search budget for this cycle is spent. Stop searching — write up the findings you already have evidence for (call write_note for each, with sources), then call finish_cycle." Wait! The tool returned a message saying the web_search budget is spent. Let's see if we can fetch the J&J press release by looking at the exact URL or searching for it. Oh, we cannot search anymore, but we can try to find the correct URL or fetch another page if we have the URL. Wait, is the `web_search` tool budget spent? Yes, the tool returned a message saying the budget is spent. Let's see if we can use `web_fetch` on a different URL if we can find one, or if we can write notes based on the information we already have. Let's check what information we have on **IMAAVY (nipocalimab-aahu)**: - Approved by the FDA on August 24, 2026. - First-ever treatment for warm autoimmune hemolytic anemia (wAIHA). - It is an immunoselective FcRn blocker designed to target and reduce pathogenic IgG autoantibodies while preserving B-cell function (from the description in our previous search). - Developed by Johnson & Johnson. Let's double check if we can fetch a page about nipocalimab. Since we can't search, we can try to guess a URL or write the notes based on the high-quality summaries we received. Wait, the rules say: "Every substantive finding MUST cite at least one real source you actually consulted THIS cycle — a web page you fetched, an HN story or comment you read, etc." We have fetched several pages this cycle: 1. `https://xspraypharma.com/modular_finance_pressmeddelande/xspray-pharma-receives-complete-response-letter-crl-from-fda-for-dasynoc/` (Xspray Dasynoc CRL) - Fetched successfully. 2. `https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/` (Merck/Moderna cancer vaccine Phase 3) - Fetched successfully. 3. `https://investor.regeneron.com/news-releases/news-release-details/pasatrutm-garetosmab-grts-first-and-only-fda-approved-treatment` (Regeneron Pasatru FDA approval) - Fetched successfully. 4. `https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-us-fda-approval-genglycostm-gene-therapy` (Ultragenyx Genglycos FDA approval) - Fetched successfully. These four are fully fetched primary sources! We can write 4 high-quality notes based on these fetched pages. What about nipocalimab (Imaavy)? We tried to fetch the J&J press release, but it failed with a 404 error, and our search budget is spent. Since we didn't successfully fetch a full page about nipocalimab, let's not write a substantive note about it this cycle to strictly adhere to the rule: "Every substantive finding MUST cite at least one real source you actually consulted THIS cycle — a web page you fetched, an HN story or comment you read, etc." We can instead record a thread to monitor it, or write a watch for it if there's a future milestone, but since it was just approved today, we can record a thread/watch for its launch or other FcRn indications. Let's carefully read the details of our findings and construct the notes. ### Finding 1: Xspray Pharma's Dasynoc CRL (Manufacturing Issues) - **Slug**: `xspray-pharma-dasynoc-crl-manufacturing-issues` (Wait, let's check if there is an existing slug. The list of prior findings has: none for Xspray. Wait, let's check if there is an open thread or watch: "Monitor Xspray's formal resubmission of its NDA for Dasynoc to the FDA..."). Since there is no existing slug in the "Relevant prior findings" block, let's mint a durable slug: `xspray-pharma-dasynoc-regulatory-path`. - **Title**: FDA Issues Fourth Complete Response Letter to Xspray Pharma's Dasynoc Over CDMO Issues - **Content**: On August 19, 2026, Xspray Pharma received its fourth Complete Response Letter (CRL) from the FDA for Dasynoc (an amorphous formulation of dasatinib) for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The rejection was driven entirely by outstanding Good Manufacturing Practice (GMP) observations at its third-party contract manufacturer, NerPharMa, and a request for additional consecutive commercial-scale batch data. Crucially, the FDA did not raise any questions regarding Dasynoc's clinical data, bioequivalence, or stability, and the risk of medication error from prior CRLs has been resolved. Xspray plans to resubmit the NDA as soon as possible in 2026. - **Sources**: - `https://xspraypharma.com/modular_finance_pressmeddelande/xspray-pharma-receives-complete-response-letter-crl-from-fda-for-dasynoc/` Let's record an event for the watch `01a030ca-9697-72f4-addf-96043b43eb73` (Xspray Pharma NDA resubmission for Dasynoc). The watch description was: "Monitor Xspray's formal resubmission of its NDA for Dasynoc to the FDA following the resolution of NerPharMa's manufacturing deficiencies and the generation of consecutive commercial-scale batch data." Wait, since they got a CRL instead of an approval, and are now planning to resubmit *again* in 2026, the resubmission from the previous cycle has been resolved by this CRL, but a new resubmission is required. Let's record an event on this watch. The watch should probably remain open or be resolved, but since it's a one_shot watch for resubmission, wait, let's see if we should resolve it or keep it open. The watch is: "Monitor Xspray's formal resubmission of its NDA...". Since they have not yet resubmitted *this* new round, let's record an event with `resolves: false` to track the upcoming resubmission in late 2026. ### Finding 2: Merck and Moderna's Personalized mRNA Cancer Vaccine (INTerpath-001) - **Slug**: `merck-moderna-mrna-cancer-vaccine-melanoma-interpath` - **Title**: Merck and Moderna Announce First Landmark Phase 3 Win for Personalized mRNA Cancer Vaccine in Melanoma - **Content**: On August 19, 2026, Merck and Moderna announced positive topline results from the Phase III INTerpath-001 trial of intismeran autogene (V940 / mRNA-4157) in combination with Keytruda (pembrolizumab) as an adjuvant treatment for patients with completely resected Stage IIB-IV melanoma. The trial met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS) at a pre-specified interim analysis, demonstrating statistically significant and clinically meaningful improvements over Keytruda alone. This represents the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and an mRNA-based cancer therapy, validating the personalized cancer vaccine platform. The companies plan to present detailed data at an upcoming medical meeting and engage with global regulators on filing submissions. - **Sources**: - `https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/` Wait, we have a watch: "Merck and Moderna BLA submission for intismeran autogene mRNA cancer vaccine in melanoma" (id `01a01c33-a9b2-7ac7-b286-c7d9b8d78905`). Let's record an event on it because they just announced the positive Phase 3 results that will support the BLA. The watch is `one_shot` and is for the *submission* of the BLA. Since the BLA has not yet been formally submitted (they are "engaging with regulators on filing submissions"), this watch should remain open (`resolves: false`), but we can record an event summarizing this Phase 3 success. ### Finding 3: FDA Approval of Regeneron's Pasatru (garetosmab-grts) for FOP - **Slug**: `regeneron-pasatru-garetosmab-fda-approval-fop` - **Title**: FDA Approves Regeneron's Pasatru as Second Treatment for Rare Bone-Forming Disorder FOP - **Content**: On August 19, 2026, the FDA approved Regeneron's Pasatru (garetosmab-grts), an intravenous activin A-neutralizing monoclonal antibody, to reduce the formation of new abnormal bone growth (heterotopic ossification, HO) and clinician-assessed flare-ups in adults (18 years and older) with Fibrodysplasia Ossificans Progressiva (FOP). Pasatru is the second approved drug for FOP in the U.S. (following Ipsen's Sohonos in 2023), but the first to show a reduction in both new HO lesions and clinician-assessed flare-ups in a placebo-controlled Phase III trial (the OPTIMA trial), demonstrating a 90% or greater reduction in new HO lesions at 56 weeks. It is administered once monthly via a one-hour intravenous infusion. Regeneron plans to launch the Phase III OPTIMA 2 trial in pediatric and adolescent patients later this year. - **Sources**: - `https://investor.regeneron.com/news-releases/news-release-details/pasatrutm-garetosmab-grts-first-and-only-fda-approved-treatment` - `https://www.ifopa.org/us-fda-approves-regeneron-pharmaceuticals-garetosmab-treatment-fop` Wait, we have a watch: "Regeneron Phase 3 OPTIMA 2 trial initiation of Pasatru in pediatric FOP" (id `01a02ba3-c32b-7413-9840-06693a558ed9`). Since the approval press release explicitly states that "A Phase 3 trial of Pasatru in adolescents and children with FOP, OPTIMA 2, is planned to begin later this year," this watch remains open (`resolves: false`). We can record an event noting that the adult approval has been secured and the pediatric trial is on track for later in 2026. ### Finding 4: FDA Accelerated Approval of Ultragenyx's Genglycos for GSDIa - **Slug**: `ultragenyx-genglycos-gene-therapy-fda-approval-gsdia` - **Title**: FDA Grants Accelerated Approval to Ultragenyx's Genglycos, First Gene Therapy for Glycogen Storage Disease Type Ia - **Content**: On August 19, 2026, the FDA granted accelerated approval to Ultragenyx's Genglycos (pariglasgene brecaparvovec-opnr; formerly DTX401), a one-time liver-directed AAV8 gene therapy, for adult and pediatric patients 8 years and older with glycogen storage disease type Ia (GSDIa). Genglycos is the first approved treatment that targets the underlying genetic cause of GSDIa (enzyme glucose-6-phosphatase deficiency), which prevents the body from properly breaking down stored glycogen into glucose. The therapy significantly reduces the round-the-clock cornstarch requirements that patients depend on to prevent life-threatening hypoglycemia, demonstrating a statistically significant 31% mean reduction in daily cornstarch requirements versus placebo in the 48-week Phase III GlucoGene study. The list price is set at $2.7 million. Post-marketing requirements include providing two years of safety and efficacy clinical data from 50 patients who receive the therapy commercially and 20 control patients. - **Sources**: - `https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-us-fda-approval-genglycostm-gene-therapy` - `https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-aged-8-years-and-older-glycogen-storage-disease-type-ia` Let's write these four findings as notes. Let's make sure we follow the formatting rules exactly: - NO YAML frontmatter. - First heading must be `# <Title>`. - Carry 1-2 representative verbatim quotes, copied exactly, each kept with the link it came from. - Link other findings using wikilinks `[[slug]]` if applicable (none of these overlap directly with existing slugs, but let's double check if there are any connections). Let's write the first note: `xspray-pharma-dasynoc-regulatory-path`. Let's review the exact quote from Xspray's press release: > "The FDA’s Complete Response Letter relates to the previously communicated observations at NerPharMa, concerning outstanding GMP (Good Manufacturing Practice) observations, as well as a request for additional commercial scale consecutive batch data following already implemented corrective actions. Importantly, the FDA has not raised questions regarding Dasynoc's clinical data, bioequivalence or stability. Furthermore, the risk of medication error raised in previous CRLs has been resolved." And Blake Leitch, CEO of Xspray Pharma, comments: > “The CRL confirms that the remaining uncertainty is now linked to NerPharMa sufficiently addressing the FDAs observations at their manufacturing site and batch data from consecutive manufacturing runs being provided. As expected, this will require a NDA resubmission." Let's write this note using `write_note`. Let's state our intent first. I will write the note for Xspray Pharma's Dasynoc CRL.

I will write the first finding regarding Xspray Pharma's fourth Complete Response Letter for Dasynoc.

I will write the research finding for Xspray Pharma's fourth Complete Response Letter (CRL) for Dasynoc.

I will now write the second finding regarding Merck and Moderna's Phase III clinical trial win for their personalized mRNA cancer vaccine, intismeran autogene, in combination with Keytruda for resected melanoma.